Edwards Lifesciences Corp Earnings Summary — Q1 2026

• Revenue grew 16.7% year-over-year to $1.65 billion, marking a significant acceleration from previous quarters.
• Operating income rebounded sharply to $477.6 million after a depressed Q4 2025, supported by lower SG&A and R&D relative to total revenue.
• The company continues to maintain a highly conservative capital structure with zero long-term debt noted in management commentary.
• Net income to common shareholders reached $380.7 million, showing steady 6.34% growth above the prior year's adjusted figures.
• Earnings quality is bolstered by the divestiture of the non-core Critical Care business, focusing efforts on high-growth structural heart therapies.
• Shareholder dilution is minimal, with basic shares outstanding decreasing 1.21% YoY to 579 million due to ongoing buyback programs.

Management remains focused on expanding the TAVR market and pivoting into transcatheter therapies for mitral and tricuspid valve disease, aiming for consistent high-quality compounding growth.

Improving

A strong recovery in quarterly operating margins (from 9.6% in Q4 to 28.9% in Q1) and accelerating revenue growth indicates a successful start to the 2026 fiscal year.

The outlook is robust as the company leverages its massive installation base and high switching costs to defend its TAVR dominance while innovating in structural heart therapies.